中国住院COVID-19幸存者的两年健康结局
该纵向队列研究纳入武汉2家COVID-19定点医院2020年2月12日至4月10日出院的3988例幸存者,其中1864例完成1年和2年电话随访。出院2年时370例(19.8%)仍有症状,包括224例(12.0%)持续症状和146例(7.8%)新发或加重症状;最常见为疲劳、胸闷、焦虑、呼吸困难、肌痛。多数症状随时间缓解,但呼吸困难发生率无显著变化(1年2.6%[49例] vs 2年2.0%[37例])。ICU入住者持续症状风险(OR 2.69;95%CI 1.02-7.06;P=0.04)和CAT≥10风险(OR 2.83;95%CI 1.21-6.66;P=0.02)更高。
要点
- 出院2年时19.8%(370/1864)仍有症状,其中12.0%(224例)为持续症状,7.8%(146例)为新发或加重症状。
- ICU入住者持续症状风险更高(OR 2.69;95%CI 1.02-7.06;P=0.04),CAT≥10风险也更高(OR 2.83;95%CI 1.21-6.66;P=0.02)。
- 2年时6.2%(116例)CAT总分≥10,提示部分幸存者存在需关注的气道症状负担。
- 呼吸困难发生率1年2.6%(49例)与2年2.0%(37例)无显著变化,其余多数症状随时间缓解。
- 结果与病毒原始株相关,对Omicron变异株感染的相关性尚不清楚。
适用人群与场景
- 2020年2月12日至4月10日在武汉2家COVID-19定点医院住院并存活出院的COVID-19患者,完成1年和2年电话随访者共1864例(中位[IQR]年龄58.5[49.0-68.0]岁;男性926例[49.7%])。
- 疾病严重程度按世界卫生组织COVID-19指南定义。
诊断标准与关键阈值
- COVID-19疾病严重程度按世界卫生组织COVID-19指南定义。
- CAT总分≥10定义为2年随访时气道症状负担的阈值。
研究设计与关键结果
- 研究类型:纵向队列研究;地点:中国武汉2家COVID-19定点医院;随访:出院后1年和2年电话访谈,2年随访于2022年3月1日至4月6日进行。
- 3988例COVID-19幸存者中,1864例完成1年和2年随访;出院至2年随访的中位(IQR)时间为730(719-743)天。
- 出院2年时370例(19.8%)仍有症状:224例(12.0%)为持续症状,146例(7.8%)为新发或加重症状;最常见症状为疲劳、胸闷、焦虑、呼吸困难、肌痛。
- 多数症状随时间缓解,但呼吸困难发生率无显著变化:1年2.6%(49例)vs 2年2.0%(37例)。
- 2年时116例(6.2%)CAT总分≥10。
- ICU入住者持续症状风险更高(OR 2.69;95%CI 1.02-7.06;P=0.04),CAT≥10风险更高(OR 2.83;95%CI 1.21-6.66;P=0.02)。
证据类型、等级与局限
- 证据类型:纵向队列研究。
- 局限:原文未报告局限性。
- 作者指出结果与病毒原始株相关,对Omicron变异株感染的相关性尚不清楚。
对床旁实践的改变
- 对住院COVID-19幸存者,尤其ICU入住者,出院后2年仍应评估持续症状(疲劳、胸闷、焦虑、呼吸困难、肌痛)及CAT评分。
- ICU入住者持续症状风险(OR 2.69;95%CI 1.02-7.06;P=0.04)和CAT≥10风险(OR 2.83;95%CI 1.21-6.66;P=0.02)更高,随访中可重点关注。
- 作者认为结果与病毒原始株相关,对Omicron变异株感染的相关性尚不清楚。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Relatively little is known about the persistence of symptoms in patients with COVID-19 for more than 1 year after their acute illness.
OBJECTIVE: To assess the health outcomes among hospitalized COVID-19 survivors over 2 years and to identify factors associated with increased risk of persistent symptoms.
DESIGN, SETTING, AND PARTICIPANTS: This was a longitudinal cohort study of patients who survived COVID-19 at 2 COVID-19-designated hospitals in Wuhan, China, from February 12 to April 10, 2020. All patients were interviewed via telephone at 1 year and 2 years after discharge. The 2-year follow-up study was conducted from March 1 to April 6, 2022. Statistical analysis was conducted from April 20 to May 5, 2022. The severity of disease was defined by World Health Organization guideline for COVID-19.
EXPOSURES: COVID-19.
MAIN OUTCOMES AND MEASURES: The main outcome was symptom changes over 2 years after hospital discharge. All patients completed a symptom questionnaire for evaluation of symptoms, along with a chronic obstructive pulmonary disease assessment test (CAT) at 1-year and 2-year follow-up visits.
RESULTS: Of 3988 COVID-19 survivors, a total of 1864 patients (median [IQR] age, 58.5 [49.0-68.0] years; 926 male patients [49.7%]) were available for both 1-year and 2-year follow-up visits. The median (IQR) time from discharge to follow-up at 2 years was 730 (719-743) days. At 2 years after hospital discharge, 370 patients (19.8%) still had symptoms, including 224 (12.0%) with persisting symptoms and 146 (7.8%) with new-onset or worsening of symptoms. The most common symptoms were fatigue, chest tightness, anxiety, dyspnea, and myalgia. Most symptoms resolved over time, but the incidence of dyspnea showed no significant change (1-year vs 2-year, 2.6% [49 patients] vs 2.0% [37 patients]). A total of 116 patients (6.2%) had CAT total scores of at least 10 at 2 years after discharge. Patients who had been admitted to the intensive care unit had higher risks of persistent symptoms (odds ratio, 2.69; 95% CI, 1.02-7.06; P = .04) and CAT scores of 10 or higher (odds ratio, 2.83; 95% CI, 1.21-6.66; P = .02).
CONCLUSIONS AND RELEVANCE: In this cohort study, 2 years after hospital discharge, COVID-19 survivors had a progressive decrease in their symptom burden, but those with severe disease during hospitalization, especially those who required intensive care unit admission, had higher risks of persistent symptoms. These results are related to the original strain of the virus, and their relevance to infections with the Omicron variant is not known.
参考来源
- Yang X, Hou C, Shen Y, et al. Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in China. JAMA Netw Open. 2022. PMID: 36107425. doi:10.1001/jamanetworkopen.2022.31790
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。